Disease Landscape and Forecast Insights

Accountable care organizations (ACOs), in which providers are held accountable for the costs of treating a payer’s patent population, will become more the rule than the exception in a year, as…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…

Owing to the heterogeneity of cancer, oncology markets are increasingly focusing on personalized therapy approaches that are expected to provide greater efficacy gains. Driving this trend are…

Gastric cancer (GC) is a major public health burden in China and is the third leading cause of cancer-related deaths in the country. Although chemotherapy is the mainstay of treatment, prescribing…

Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myelogenous leukemia (CML) over the last decade. However, as 2013-approved second-generation TKIs Bosulif (Pfizer’s…

Serious Gram-negative (GN) pathogens are clinically-important pathogens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a…

Last Updated 1 May 2014 The market for disease-modifying multiple sclerosis (MS) therapies is in the midst of transformation: three oral agents are now available—fingolimod (Novartis/Mitsubishi…

The Chinese market for hepatocellular carcinoma (HCC) therapies represents an increasingly lucrative space for many pharmaceutical companies. Although the high prices demanded by targeted brands…

Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…

What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…

What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…

TreatmentTrends: Psoriasis (EU) will cover practice dynamics, current use and future use projections for key products, perceived product ad-vantages and disadvantages. While the report does cover…